The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has given the green light for the third boost to Moderna's Spikevax vaccine, according to a statement.
As reported, the data show that a booster dose of this vaccine, 6 to 8 months after the second dose, leads to an increase in antibodies in adults whose antibodies decrease over time.
The booster dose consists of half the dose used for normal vaccination.
According to the data so far, the side effects from one booster dose are similar to those following the second dose.
The health authorities in the Member States can make recommendations for a third dose based on the local epidemiological situation, according to Coreper.
On October 4, EMA was given the green light for a booster dose of Pfizer Comirnaty vaccine for people over 18 at least six months after the second dose, and an additional dose recommendation for people with severely weakened immune systems for both vaccines. at least 28 days after the second dose.